51. Discovery of 2H-Chromen-2-one Derivatives as G Protein-Coupled Receptor-35 Agonists
- Author
-
Lai Wei, Ping Wang, Xinmiao Liang, Lala Qu, Tao Hou, Jiaqi Li, Yaopeng Zhao, Shi Liying, Xiuli Zhang, Jixia Wang, and Ye Fang
- Subjects
0301 basic medicine ,Agonist ,Stereochemistry ,medicine.drug_class ,Proton Magnetic Resonance Spectroscopy ,Druggability ,01 natural sciences ,Mass Spectrometry ,Receptors, G-Protein-Coupled ,03 medical and health sciences ,Drug Discovery ,medicine ,Potency ,Humans ,Benzopyrans ,Carbon-13 Magnetic Resonance Spectroscopy ,Receptor ,EC50 ,010405 organic chemistry ,Chemistry ,Combinatorial chemistry ,0104 chemical sciences ,030104 developmental biology ,Molecular Medicine ,G-Protein Coupled Receptor 35 ,GPR35 ,HT29 Cells - Abstract
A family of 2H-chromen-2-one derivatives were identified as G protein-coupled receptor-35 (GPR35) agonists using dynamic mass redistribution assays in HT-29 cells. The compounds with 1H-tetrazol-5-yl in 3-substituted position displayed higher potency than the corresponding carboxyl analogs, and the hydroxyl group in the 7-position also played an important role in GPR35 agonistic activity. 6-Bromo-7-hydroxy-8-nitro-3-(1H-tetrazol-5-yl)-2H-chromen-2-one (50) was found to be the most potent GPR35 agonist with an EC50 of 5.8 nM. Calculating the physicochemical properties of compounds with moderate to high potency suggested that compounds 30, 50, and 51 showed good druggability. This study provides a novel series of GPR35 agonists, and compound 50 may be a powerful tool to study GPR35.
- Published
- 2016